Investigators Use RWD to Identify Potential Alzheimer’s Drug

According to a new study using data from electronic health records (EHRs), bumetanide, a diuretic, could be used in patients with Alzheimer’s disease. The real world data (RWD) study sought to identify drugs already approved by the Food and Drug Administration (FDA) for other purposes.

“Researchers may have found new potential for a diuretic to treat Alzheimer’s disease (AD). The team, from the University of California (CA, USA), utilized real-world evidence including human brain databases. The findings have been published in Nature Aging. The diuretic, known as bumetanide, is a commonly prescribed drug already approved by the FDA.” Read more here.

(Source: Darcy Hodge, The Evidence Base, 10/14/21)